This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miranda, L. R. Articles by Kuritzkes, D. R. Search for Related Content PubMed PubMed Citation Articles by Miranda, L. R. Articles by Kuritzkes, D. R.

The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations

Section of Retroviral Therapeutics, Brigham and Women's Hospital, and Division of AIDS, Harvard Medical School, Boston, Massachusetts,¹ McGill University AIDS Centre, Lady Davis Institute-Jewish General Hospital, and Departments of Microbiology and Immunology and Experimental Medicine, McGill University, Montréal, Québec, Canada²

Received 19 December 2004/ Returned for modification 8 March 2005/ Accepted 5 April 2005

Thymidine analog mutations (TAMs) in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) confer resistance to zidovudine (AZT) by increasing the rate of ATP-dependent phosphorolysis of the terminal nucleotide monophosphate (primer unblocking). By contrast, the L74V mutation, which confers resistance to didanosine, sensitizes HIV-1 to AZT and partially restores AZT susceptibility when present together with one or more TAMs. To compare rates of primer unblocking in RTs carrying different clusters of TAMs and to explore the biochemical mechanism by which L74V affects AZT susceptibility, ATP-mediated rescue of AZT-blocked DNA synthesis was assayed using a series of purified recombinant RTs. Rates of primer unblocking were higher in the 67N/70R/219Q RT than in the 41L/210W/215Y enzyme and were similar to rates observed with an RT carrying six TAMs (41L/67N/70R/210W/215Y/219Q). The presence of 74V in an otherwise wild-type RT reduced the rate of primer unblocking to a degree similar to that observed with the M184V mutation for lamivudine resistance, which also sensitizes HIV-1 to AZT. Introduction of 74V into RTs carrying TAMs partially counteracted the effect of TAMs on the rate of primer unblocking. The effect of 74V was less marked than that of the 184V mutation in the 67N/70R/219Q and 41L/210W/215Y RTs but similar in the RT carrying six TAMs. These results demonstrate that L74V enhances AZT susceptibility by reducing the extent of its removal by ATP-dependent phosphorolysis and provides further evidence for a common mechanism by which mutations conferring resistance to didanosine and lamivudine sensitize HIV-1 to AZT.

This article has been cited by other articles:

• Zelina, S., Sheen, C.-W., Radzio, J., Mellors, J. W., Sluis-Cremer, N. (2008). Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine. Antimicrob. Agents Chemother. 52: 157-163 [Abstract] [Full Text]  
• Ntemgwa, M., Wainberg, M. A., Oliveira, M., Moisi, D., Lalonde, R., Micheli, V., Brenner, B. G. (2007). Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine. Antimicrob. Agents Chemother. 51: 3861-3869 [Abstract] [Full Text]  
• Nikolenko, G. N., Delviks-Frankenberry, K. A., Palmer, S., Maldarelli, F., Fivash, M. J. Jr., Coffin, J. M., Pathak, V. K. (2007). Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. USA 104: 317-322 [Abstract] [Full Text]  
• Wirden, M., Roquebert, B., Derache, A., Simon, A., Duvivier, C., Ghosn, J., Dominguez, S., Boutonnet, V., Ait-Arkoub, Z., Katlama, C., Calvez, V., Marcelin, A.-G. (2006). Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients.. Antimicrob. Agents Chemother. 50: 2553-2556 [Abstract] [Full Text]